Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Boston, USA
184 High Street
Boston, MA, 02110
USA

People

COO
Board of Directors
Chairman/CEO

Funding

TOTAL $10.2M
FUNDING TOTAL $10.2M
Venture Round, 4/2011
$3.2M
Series B, 5/2011
Advent Venture Partners
Shire
$7M

Tags

Prexa Pharmaceuticals

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease.

Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Recent Milestones

Videos

Screenshots

Sources

  1. Prexa Pharma raises $3.2M to target ADHD, depression, Parkinson's (masshightech.com) [edit]
  2. Prexa Pharmaceuticals Obtains $7.0 million in Series B Financing (prexainc.com) [edit]
Edit This Page
Last Edited 12/11/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy